# Research Idea Ranking

**Generated:** 2026-02-10T17:20:30.832184
**Model:** openai/gpt-5.2 (reasoning: high)
**Tokens:** 7197

---

### Rankings

**#1: The Innovation Cost of Privacy — State Data Privacy Laws and the Technology Sector**
- **Score: 74/100**
- **Strengths:** High-novelty policy setting with genuinely staggered, multi-wave adoption and strong administrative, high-frequency outcomes (QCEW, BFS) that are well-suited to modern staggered DiD methods. Outcomes (tech employment, wages, establishments, applications) are economically meaningful and plausibly responsive to compliance costs and market-structure changes.
- **Concerns:** Treatment is likely “leaky” because many multi-state firms may standardize compliance nationally (spillovers/SUTVA violations), attenuating estimates toward zero and complicating interpretation. Adoption may correlate with unobserved state tech dynamics/politics (endogenous timing), and some effective dates are mid-quarter, requiring careful exposure coding.
- **Novelty Assessment:** **High.** There is work on GDPR and on CCPA (single-state) and privacy in general, but a 20-state staggered-rollout causal design on labor market + business formation outcomes is still relatively uncrowded.
- **DiD Assessment (staggered DiD):**
  - **Pre-treatment periods:** **Strong** (QCEW back to 2010; ample pre for all waves, including CA).
  - **Selection into treatment:** **Marginal** (political economy + tech-sector presence likely predict adoption; not a clearly exogenous shock).
  - **Comparison group:** **Marginal** (never-treated states exist in number, but treated states may be systematically higher-tech; needs strong diagnostics/weighting).
  - **Treatment clusters:** **Strong** (~20 treated states; inference more credible than “few treated states” designs).
  - **Concurrent policies:** **Marginal** (2020–2026 includes COVID-era labor shocks and other state tech/regulatory initiatives; stagger helps, but confounding is plausible).
  - **Outcome-Policy Alignment:** **Marginal–Strong** (compliance costs/entry barriers should show up in establishments and employment in data-intensive industries; not perfect because laws apply across sectors and often exempt very small firms).
  - **Data-Outcome Timing:** **Strong (conditional on coding)** (quarterly outcomes allow defining treatment as “first full quarter after effective date”; must not treat partial-exposure quarters as fully treated).
  - **Outcome Dilution:** **Marginal** (many NAICS 51 firms are affected, but exemptions and national compliance standardization likely dilute; effect may be clearer for establishment dynamics and smaller firms than for aggregate employment).
- **Recommendation:** **PURSUE (conditional on: (i) explicit handling of spillovers/national-standard compliance—e.g., stronger effects for single-state/smaller firms, border-county tests, or exposure measures based on in-state consumer share; (ii) treatment timing defined by first full quarter of exposure; (iii) robustness to alternative control constructions such as synthetic DiD / weighted controls for high-tech states).**

---

**#2: Can You Cap Your Way to Health? State Insulin Copay Caps and Diabetes Outcomes**
- **Score: 46/100**
- **Strengths:** Highly policy-relevant question with many treated states and long pre-periods; the “downstream health outcomes” angle is more novel than the existing utilization/OOP literature. Mortality data are cleanly measured (WONDER) and not subject to survey reporting bias.
- **Concerns:** The treated population is a small and poorly observed subset (state-regulated *commercial fully-insured* plans), while the proposed outcomes are mostly for **all diabetics** (or even whole-population mortality), creating severe dilution and likely false nulls. Annual state-level outcomes plus varied effective dates and slow clinical response times further weaken interpretability.
- **Novelty Assessment:** **Moderate.** Copay caps themselves are heavily studied for spending/utilization; health outcomes are less studied, but the reason is partly data/identification difficulty rather than oversight.
- **DiD Assessment (staggered DiD):**
  - **Pre-treatment periods:** **Strong** (BRFSS 2011+, WONDER 1999+).
  - **Selection into treatment:** **Marginal** (likely related to affordability crises and political preferences; may correlate with underlying diabetes trends and state health policy activism).
  - **Comparison group:** **Marginal** (never-treated states exist, but treated states may differ systematically in health policy environment).
  - **Treatment clusters:** **Strong** (≈29+ states + DC).
  - **Concurrent policies:** **Marginal–Weak** (states enacting caps often pursue other diabetes/drug policies; hard to rule out coincident reforms affecting adherence/mortality).
  - **Outcome-Policy Alignment:** **Marginal** (mechanism is plausible—lower OOP → less rationing → better health—but the policy does not apply to most diabetics captured in BRFSS/WONDER aggregates).
  - **Data-Outcome Timing:** **Marginal** (state-year outcomes average partial exposure when laws start mid-year; mortality/management may respond with lags, blurring “event time”).
  - **Outcome Dilution:** **Weak (dealbreaker as proposed).** Only a small fraction of diabetics are insulin users, and only a subset of those are in state-regulated fully insured commercial plans; for mortality, the affected share is almost certainly **<10%** of the outcome sample.
- **Recommendation:** **SKIP** *(unless the design is rebuilt around data that isolates the treated population—e.g., commercial claims/APCD segments where plan regulation status is observable, or BRFSS microdata restricted to insulin users ages 18–64 with private coverage plus a credible adjustment for ERISA exposure; and outcomes closer to the mechanism, such as insulin fills/adherence or diabetes acute-complication hospitalizations among the treated group).*  

---

**#3: From Nairobi to Nashville — Community Health Worker Medicaid Integration and Population Health**
- **Score: 34/100**
- **Strengths:** Important policy question with a plausibly impactful workforce/intervention channel; staggered SPA approvals provide a potential quasi-experimental timeline. If linked to the right outcomes/population (Medicaid enrollees), this could be valuable.
- **Concerns:** As proposed, outcomes are largely **statewide** (BRFSS population health, all-cause infant mortality, broad PQI), while the policy affects a small subset (Medicaid enrollees receiving CHW services) with likely slow and heterogeneous uptake—classic severe dilution plus treatment mismeasurement. Adoption is also deeply entangled with broader Medicaid/health system reforms (expansions, waivers, delivery-system changes), making confounding highly likely.
- **Novelty Assessment:** **Moderate.** CHW programs and Medicaid innovations are widely studied; the specific “CHW reimbursement SPA” hook is less saturated, but not entirely new, and the main challenge is not a literature gap—it’s credible identification and measurement.
- **DiD Assessment (staggered DiD):**
  - **Pre-treatment periods:** **Strong** (long pre windows available).
  - **Selection into treatment:** **Weak** (states choosing CHW reimbursement are likely those already on strong improvement trajectories / reform agendas; timing plausibly responds to health system conditions).
  - **Comparison group:** **Weak** (never-treated states may be structurally different—often different Medicaid generosity/political economy—raising parallel-trends risk).
  - **Treatment clusters:** **Strong** (~20 treated states).
  - **Concurrent policies:** **Weak** (Medicaid expansions/1115 waivers/managed-care redesigns commonly co-move with CHW SPAs and affect the same outcomes).
  - **Outcome-Policy Alignment:** **Marginal** (preventable hospitalizations could respond, but only for Medicaid beneficiaries actually reached by CHWs; broad state health outcomes are not tightly linked to the billing policy itself).
  - **Data-Outcome Timing:** **Marginal–Weak** (SPA approval/effective dates ≠ real service scale-up; uptake lags mean “treated year” may have little exposure).
  - **Outcome Dilution:** **Weak (dealbreaker as proposed).** CHW-reimbursed services plausibly touch **well under 10%** of the state population; statewide averages will mechanically wash out effects.
- **Recommendation:** **SKIP** *(unless redesigned with Medicaid-enrollee-level or safety-net-provider-level outcomes and credible exposure measures, e.g., Medicaid claims for CHW-billable codes, Medicaid-specific PQIs, or hospital discharge data stratified by payer; plus explicit handling of concurrent Medicaid reforms and a strategy to isolate CHW-SPA variation from broader delivery-system changes).*  

---

### Summary

This is a mixed batch: **Idea 1** is the clear front-runner because it combines a relatively novel policy setting with high-frequency administrative data and a plausible staggered DiD design. **Ideas 2 and 3** both run into “fatal” DiD problems as currently scoped—especially **outcome dilution** (and, for Idea 3, major concurrent-policy confounding and treatment mismeasurement)—making null results likely and hard to interpret. If you pursue only one first, pursue **Idea 1**.